Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech/Wellcome TPA suit

Executive Summary

Genentech says it won decisions in "all matters" of the tissue plasminogen activator patent and antitrust litigation with Burroughs Wellcome and Genetics Institute ("The Pink Sheet" March 12, T&G-4). In an April 6 jury decision in Wilmington, Delaware Federal Court, the jury found that "Wellcome and Genetics Institute infringed three Genentech TPA patents and upheld the validity and enforceability of those patents, but did not award any monetary damages," Genentech said. The jury also denied Wellcome's antitrust claims against Genentech as well as Genetics Institute's claim of unfair competition, according to Genentech. Genentech plans to file for a court injunction preventing Wellcome and Genetics Institute from marketing their first and second generation TPA products in the U.S.

You may also be interested in...



Hikma And Civica Ship Eight Essential Injectables

Hikma and Civica Rx have announced the launch of a first wave of eight essential injectable medicines, including heparin, as part of a deal struck between the two firms earlier this year.

AstraZeneca's Calquence Steps Up in First-Line CLL

A PFS benefit and favorable tolerability profile associated with AstraZeneca’s BTK inhibitor acalabrutinib used first-line in CLL, when given alone or combined with obinutuzumab, may serve it well against entrenched competitors and BTK inhibitors in clinical development.

Amneal Takes Control Of AvKARE In US

Amneal has acquired a majority stake in manufacturer and wholesaler AvKARE, giving the firm access to the “large, complex and growing federal healthcare market.”

UsernamePublicRestriction

Register

PS017227

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel